{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T01:46:59Z","timestamp":1783648019922,"version":"3.55.0"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular and Cellular Endocrinology"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.mce.2019.110585","type":"journal-article","created":{"date-parts":[[2019,9,16]],"date-time":"2019-09-16T11:05:08Z","timestamp":1568631908000},"page":"110585","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["In vitro cytotoxicity of cabazitaxel in adrenocortical carcinoma cell lines and human adrenocortical carcinoma primary cell cultures\u2606"],"prefix":"10.1016","volume":"498","author":[{"given":"Martina","family":"Fragni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilian Patricia","family":"Palma Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Rossini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Abate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Cosentini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Salvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Vezzoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro Luigi","family":"Poliani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Bosisio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constanze","family":"Hantel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido A.M.","family":"Tiberio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Grisanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Memo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4171-2851","authenticated-orcid":false,"given":"Massimo","family":"Terzolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Berruti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Sigala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.mce.2019.110585_bib1","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.phrs.2011.06.009","article-title":"Muscarinic receptors stimulate cell proliferation in the human urothelium-derived cell line UROtsa","volume":"64","author":"Arrighi","year":"2011","journal-title":"Pharmacol. Res."},{"issue":"1","key":"10.1016\/j.mce.2019.110585_bib2","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/cdd.2017.169","article-title":"How does p53 induce apoptosis and how does this relate to p53-mediated tumour suppression?","volume":"25","author":"Aubrey","year":"2018","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.mce.2019.110585_bib3","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1158\/1535-7163.MCT-14-0265","article-title":"Antiproliferative mechanism of action of the novel taxane cabazitaxel as compared with the parent compound docetaxel in MCF7 breast cancer cells","volume":"13","author":"Azarenko","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.mce.2019.110585_bib4","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1210\/jcem-73-1-18","article-title":"Mitotane enhances cytotoxicity of chemotherapy in cell lines expressing a multidrug resistance gene (mdr-1\/P-glycoprotein) which is also expressed by adrenocortical carcinoma","volume":"73","author":"Bates","year":"1991","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.mce.2019.110585_bib5","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1677\/erc.1.01025","article-title":"Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial","volume":"12","author":"Berruti","year":"2005","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.mce.2019.110585_bib6","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1517\/14728214.13.3.497","article-title":"Emerging drugs for adrenocortical carcinoma","volume":"13","author":"Berruti","year":"2008","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"10.1016\/j.mce.2019.110585_bib7","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1530\/EJE-11-0918","article-title":"Phase II study of weekly paclitaxel and sorafenib as second\/third-line therapy in patients with adrenocortical carcinoma","volume":"166","author":"Berruti","year":"2012","journal-title":"Eur. J. Endocrinol."},{"issue":"Suppl. 7","key":"10.1016\/j.mce.2019.110585_bib8","doi-asserted-by":"crossref","first-page":"vii131","DOI":"10.1093\/annonc\/mds231","article-title":"Adrenal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"23","author":"Berruti","year":"2012","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.mce.2019.110585_bib9","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.tibs.2004.03.006","article-title":"Advances in protein kinase B signalling: AKTion on multiple fronts","volume":"29","author":"Brazil","year":"2004","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.mce.2019.110585_bib10","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1158\/1078-0432.CCR-11-1590","article-title":"Molecular pathways: regulation and therapeutic implications of multidrug resistance","volume":"18","author":"Chen","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.mce.2019.110585_bib11","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","article-title":"Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors","volume":"22","author":"Chou","year":"1984","journal-title":"Adv. Enzym. Regul."},{"key":"10.1016\/j.mce.2019.110585_bib12","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.58.3.10","article-title":"Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies","volume":"58","author":"Chou","year":"2006","journal-title":"Pharmacol. Rev."},{"issue":"5","key":"10.1016\/j.mce.2019.110585_bib13","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv041","article-title":"EGFR amplified and overexpressing glioblastomas and associate with better response to adjuvant metronomic temozolomide","volume":"107","author":"Cominelli","year":"2015","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.mce.2019.110585_bib14","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","article-title":"TROPIC Investigators. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial","volume":"376","author":"de Bono","year":"2010","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.mce.2019.110585_bib15","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00204-014-1430-4","article-title":"Biology of the cell cycle inhibitor p21(CDKN1A): molecular mechanisms and relevance in chemical toxicology","volume":"89","author":"Dutto","year":"2015","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.mce.2019.110585_bib16","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1080\/07435809609043766","article-title":"Effects of taxol on the human NCI-H295 adrenocortical carcinoma cell line","volume":"22","author":"Fallo","year":"1996","journal-title":"Endocr. Res."},{"key":"10.1016\/j.mce.2019.110585_bib17","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1159\/000007104","article-title":"Paclitaxel is an effective antiproliferative agent on the human NCI-H295 adrenocortical carcinoma cell line","volume":"44","author":"Fallo","year":"1998","journal-title":"Chemotherapy"},{"key":"10.1016\/j.mce.2019.110585_bib18","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1200966","article-title":"Combination chemotherapy in advanced adrenocortical carcinoma","volume":"366","author":"Fassnacht","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.mce.2019.110585_bib19","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-18-0608","article-title":"European society of endocrinology clinical practice guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the european network for the study of adrenal tumors","volume":"179","author":"Fassnacht","year":"2018","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.mce.2019.110585_bib20","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.euf.2015.06.005","article-title":"Systemic therapy in locally advanced or metastatic adrenal cancers: a critical appraisal and clinical trial update","volume":"1","author":"Ferrari","year":"2016","journal-title":"Eur. Urol. Focus"},{"key":"10.1016\/j.mce.2019.110585_bib21","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.yexcr.2014.02.025","article-title":"GPNMB\/OA protein increases the invasiveness of human metastatic prostate cancer cell lines DU145 and PC3 through MMP-2 and MMP-9 activity","volume":"323","author":"Fiorentini","year":"2014","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.mce.2019.110585_bib22","doi-asserted-by":"crossref","first-page":"4594","DOI":"10.1210\/jc.2016-2414","article-title":"Antisecretive and antitumor activity of abiraterone acetate in human adrenocortical cancer: a preclinical study","volume":"101","author":"Fiorentini","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"6","key":"10.1016\/j.mce.2019.110585_bib23","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/j.eururo.2013.07.022","article-title":"Taxane mechanisms of action: potential implications for treatment sequencing in metastatic castration-resistant prostate cancer","volume":"65","author":"Fitzpatrick","year":"2014","journal-title":"Eur. Urol."},{"key":"10.1016\/j.mce.2019.110585_bib24","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s00210-016-1224-8","article-title":"The miR-21\/PTEN\/Akt signaling pathway is involved in the anti-tumoral effects of zoledronic acid in human breast cancer cell lines","volume":"389","author":"Fragni","year":"2016","journal-title":"Naunyn Schmiedeb. Arch. Pharmacol."},{"key":"10.1016\/j.mce.2019.110585_bib25","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1007\/s12020-018-1795-x","article-title":"In vitro antitumor activity of progesterone in human adrenocortical carcinoma","volume":"63","author":"Fragni","year":"2019","journal-title":"Endocrine"},{"key":"10.1016\/j.mce.2019.110585_bib26","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/s12020-014-0374-z","article-title":"Mitotane enhances doxorubicin cytotoxic activity by inhibiting P-gp in human adrenocortical carcinoma cells","volume":"47","author":"Gagliano","year":"2014","journal-title":"Endocrine"},{"key":"10.1016\/j.mce.2019.110585_bib27","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/nrd3254","article-title":"Cabazitaxel","volume":"9","author":"Galsky","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.mce.2019.110585_bib28","first-page":"291","article-title":"Signal transduction pathways of taxanes-induced apoptosis","volume":"3","author":"Ganansia-Leymarie","year":"2003","journal-title":"Curr. Med. Chem. Anti Cancer Agents"},{"key":"10.1016\/j.mce.2019.110585_bib29","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.bbapap.2003.11.009","article-title":"Structure, regulation and function of PKB\/AKT--a major therapeutic target","volume":"1697","author":"Hanada","year":"2004","journal-title":"Biochim. Biophys. Acta"},{"issue":"48","key":"10.1016\/j.mce.2019.110585_bib30","doi-asserted-by":"crossref","first-page":"79292","DOI":"10.18632\/oncotarget.12685","article-title":"Targeting heterogeneity of adrenocortical carcinoma: evaluation and extension of preclinical tumor models to improve clinical translation","volume":"7","author":"Hantel","year":"2016","journal-title":"Oncotarget"},{"issue":"11","key":"10.1016\/j.mce.2019.110585_bib31","doi-asserted-by":"crossref","first-page":"4323","DOI":"10.1210\/jc.2017-01624","article-title":"Gemcitabine-based chemotherapy in adrenocortical carcinoma: a multicenter study of efficacy and predictive factors","volume":"102","author":"Henning","year":"2017","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.mce.2019.110585_bib32","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nrc1317","article-title":"Microtubules as a target for anticancer drugs","volume":"4","author":"Jordan","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.mce.2019.110585_bib33","first-page":"115","article-title":"ATP-binding cassette subfamily B member 1 (ABCB1) and subfamily C member 10 (ABCC10) are not primary resistance factors for cabazitaxel","volume":"34","author":"Kathawala","year":"2015","journal-title":"Chin. J. Canc."},{"issue":"4","key":"10.1016\/j.mce.2019.110585_bib34","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/nrclinonc.2010.228","article-title":"Mitosis is not a key target of microtubule agents in patient tumors","volume":"8","author":"Komlodi-Pasztor","year":"2011","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.mce.2019.110585_bib35","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/MED.0000000000000247","article-title":"Novel targeted therapies in adrenocortical carcinoma","volume":"23","author":"Konda","year":"2016","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"key":"10.1016\/j.mce.2019.110585_bib36","doi-asserted-by":"crossref","first-page":"709","DOI":"10.4161\/cbt.4.7.1767","article-title":"AKT activation and response to interferon-beta in human cancer cells","volume":"4","author":"Lei","year":"2005","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.mce.2019.110585_bib37","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1159\/000341444","article-title":"Matrine inhibits breast cancer growth via mir-21\/PTEN\/AktPathway in MCF-7 cells","volume":"30","author":"Li","year":"2012","journal-title":"Cell. Physiol. Biochem."},{"key":"10.1016\/j.mce.2019.110585_bib38","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1093\/annonc\/mdv329","article-title":"Prognostic factors in stage III-IV adrenocortical carcinomas (ACC): an european network for the study of adrenal tumor (ENSAT) study","volume":"26","author":"Lib\u00e9","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.mce.2019.110585_bib39","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"key":"10.1016\/j.mce.2019.110585_bib40","first-page":"685","article-title":"Pharmacogenetics of ATP-binding cassette transporters in cancer and chemotherapy","volume":"2","author":"Lockhart","year":"2003","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.mce.2019.110585_bib41","doi-asserted-by":"crossref","first-page":"25297","DOI":"10.1074\/jbc.M201869200","article-title":"Activation of the phosphatidylinositol 3-kinase\/Akt signaling pathway by retinoic acid is required for neural differentiation of SH-SY5Y human neuroblastoma cells","volume":"277","author":"Lopez-Carballo","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.mce.2019.110585_bib42","author":"Micromedex Solutions"},{"key":"10.1016\/j.mce.2019.110585_bib43","first-page":"749","article-title":"In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576","volume":"61","author":"Mistry","year":"2001","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.mce.2019.110585_bib44","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1254\/jphs.14024FP","article-title":"In vitro and in vivo effects of xanthorrhizol on human breast cancer MCF-7 cells treated with tamoxifen","volume":"125","author":"Noomhorm","year":"2014","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.mce.2019.110585_bib45","doi-asserted-by":"crossref","first-page":"4542","DOI":"10.1210\/jc.2008-0903","article-title":"Development of an adrenocorticotropin-responsive human adrenocortical carcinoma cell line","volume":"93","author":"Parmar","year":"2008","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.mce.2019.110585_bib46","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/ncb840","article-title":"Akt regulates growth by directly phosphorylating Tsc2","volume":"4","author":"Potter","year":"2002","journal-title":"Nat. Cell Biol."},{"issue":"8","key":"10.1016\/j.mce.2019.110585_bib47","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.tips.2018.05.002","article-title":"Hypoxia and noncoding RNAs in taxane resistance","volume":"39","author":"Pucci","year":"2018","journal-title":"Trends Pharmacol. Sci."},{"issue":"11","key":"10.1016\/j.mce.2019.110585_bib48","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1080\/14737140.2018.1510325","article-title":"Decision-making for adrenocortical carcinoma: surgical, systemic, and endocrine management options","volume":"18","author":"Puglisi","year":"2018","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.mce.2019.110585_bib49","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.mce.2003.12.020","article-title":"Adrenocortical cell lines","volume":"228","author":"Rainey","year":"2004","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.mce.2019.110585_bib50","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1039\/C3NP70092E","article-title":"Recent progress with microtubule stabilizers: new compounds, binding modes and cellular activities","volume":"31","author":"Rohena","year":"2014","journal-title":"Nat. Prod. Rep."},{"key":"10.1016\/j.mce.2019.110585_bib51","doi-asserted-by":"crossref","first-page":"E161","DOI":"10.1210\/jc.2010-0653","article-title":"High diagnostic and prognostic value of steroidogenic factor-1 expression in adrenal tumors","volume":"95","author":"Sbiera","year":"2010","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.mce.2019.110585_bib52","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.ccr.2005.09.006","article-title":"The BAD protein integrates survival signaling by EGFR\/MAPK and PI3K\/Akt kinase pathways in PTEN-deficient tumor cells","volume":"8","author":"She","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.mce.2019.110585_bib53","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.mce.2007.12.015","article-title":"Gene expression profile of prostate cancer cell lines: effect of nerve growth factor treatment","volume":"284","author":"Sigala","year":"2008","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.mce.2019.110585_bib54","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1677\/ERC-09-0281","article-title":"Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-\/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study","volume":"17","author":"Sperone","year":"2010","journal-title":"Endocr. Relat. Cancer"},{"issue":"3","key":"10.1016\/j.mce.2019.110585_bib55","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1530\/EJE-13-0242","article-title":"Mitotane levels predict the outcome of patients with adrenocortical carcinoma treated adjuvantly following radical resection","volume":"169","author":"Terzolo","year":"2013","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.mce.2019.110585_bib56","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s40618-013-0049-2","article-title":"Management of adrenal cancer: a 2013 update","volume":"37","author":"Terzolo","year":"2014","journal-title":"J. Endocrinol. Investig."},{"issue":"6220","key":"10.1016\/j.mce.2019.110585_bib57","doi-asserted-by":"crossref","first-page":"1260419","DOI":"10.1126\/science.1260419","article-title":"Proteomics. Tissue-based map of the human proteome","volume":"347","author":"Uhl\u00e9n","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.mce.2019.110585_bib58","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1038\/bjc.2013.229","article-title":"Treatment with docetaxel and cisplatin in advanced adrenocortical carcinoma, a phase II study","volume":"108","author":"Urup","year":"2013","journal-title":"Br. J. Canc."},{"key":"10.1016\/j.mce.2019.110585_bib59","first-page":"133","article-title":"Modulation of cytotoxic drug activity by mitotane and lonidamine in human adrenocortical carcinoma cells","volume":"14","author":"Villa","year":"1999","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.mce.2019.110585_bib60","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1038\/sj.onc.1206280","article-title":"Paclitaxel-induced apoptosis in BJAB cells proceeds via a death receptor-independent, caspases-3\/-8-driven mitochondrial amplification loop","volume":"22","author":"von Haefen","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.mce.2019.110585_bib61","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1158\/1078-0432.CCR-12-3146","article-title":"Preclinical antitumor activity of cabazitaxel, a semisynthetic taxane active in taxane-resistant tumors","volume":"19","author":"Vrignaud","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.mce.2019.110585_bib62","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.mce.2011.08.041","article-title":"Human adrenocortical carcinoma cell lines","volume":"351","author":"Wang","year":"2012","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.mce.2019.110585_bib63","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/1756-9966-30-87","article-title":"Apoptosis in cancer: from pathogenesis to treatment","volume":"30","author":"Wong","year":"2011","journal-title":"J. Exp. Clin. Cancer Res."}],"container-title":["Molecular and Cellular Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0303720719302874?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0303720719302874?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T14:10:09Z","timestamp":1759587009000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0303720719302874"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":63,"alternative-id":["S0303720719302874"],"URL":"https:\/\/doi.org\/10.1016\/j.mce.2019.110585","relation":{},"ISSN":["0303-7207"],"issn-type":[{"value":"0303-7207","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro cytotoxicity of cabazitaxel in adrenocortical carcinoma cell lines and human adrenocortical carcinoma primary cell cultures\u2606","name":"articletitle","label":"Article Title"},{"value":"Molecular and Cellular Endocrinology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mce.2019.110585","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"110585"}}